+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy



A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy



Alimentary Pharmacology & Therapeutics 19(3): 339-347



Background: An early virological response to interferon-alpha treatment is a strong predictor of sustained response, but it has never been exploited to stratify patients in clinical trials. Aim: To evaluate the efficacy of amantadine plus interferon-alpha compared with interferon-alpha alone in naive patients with chronic hepatitis C who were randomized on the basis of the early virological response to interferon-alpha. Methods: One hundred and eighty-one patients received recombinant interferon-alpha2a (3 MU three times weekly) for 2 months and 164 were evaluated for early (i.e. month 2) virological response. Hepatitis C virus (HCV) RNA-negative patients (n = 66) were randomized to receive 3 MU of interferon-alpha three times weekly, with or without amantadine (200 mg/day); HCV RNA-positive patients (n = 98) were randomized to receive 6 MU of interferon-alpha three times weekly, with or without amantadine (200 mg/day). HCV RNA-positive patients at 6 months discontinued treatment, and all others completed 12 months. Results: At month 6, HCV RNA-negative patients made up 54.2% of the interferon + amantadine group and 42.0% of the monotherapy group (P = 0.07). At month 12, HCV RNA-negative patients made up 38.5% of the interferon + amantadine group and 28.4% of the monotherapy group (N.S.). The sustained virological response rates were 21.6% and 20.9%, respectively (N.S.). Conclusion: The addition of amantadine does not enhance the sustained virological response to interferon-alpha in naive patients with chronic hepatitis C; however, an additive effect of amantadine occurs in the first 6 months, mainly in patients without an early response to monotherapy. Early response to interferon-alpha is a strong predictor of sustained virological response.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011704601

Download citation: RISBibTeXText

PMID: 14984381


Related references

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. Scandinavian Journal of Gastroenterology 34(2): 194-198, 1999

Is immunological therapy useful in chronic hepatitis C virus infection? A randomized study of interferon alpha2a plus cimetidine versus interferon alpha2a plus placebo. Hepatology 32(4 Pt 2): 443A, 2000

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Alimentary Pharmacology and Therapeutics 24(7): 1079-1086, 2006

Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group. Journal of Viral Hepatitis 5(1): 53-59, 1998

A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B. Journal of Viral Hepatitis 7(3): 225-229, 2000

A randomized controlled trial of amantadine plus interferon alpha-2a vs interferon-alpha-2a in naive patients with chronic hepatitis C randomized based on early response to interferon alpha-2a alone. Hepatology 36(4 Part 2): 589A, 2002

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antiviral Therapy 14(8): 1165-1174, 2009

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Suppl. 1): 245, 2002

Interferon-alpha2a and Systemic Corticosteroid in Monotherapy in Chronic Uveitis: Results of the Randomized Controlled BIRDFERON Study. American Journal of Ophthalmology 177: 182-194, 2017

Efficacy and safety of escitalopram, for the prevention of depressive episodes induced by PEG-interferon alpha2a and ribavirin in chronic hepatitis C patients. A double-blind, randomized, placebo-controlled trial. 2007

Interferon alpha2a induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection. Gastroenterology 120(5 Suppl. 1): A 409, 2001

Bedeutung der immunochemotherapie fur das uberleben von patienten mit metastasiertem nierenzellkarzinom - Eine retrospektive studie der therapie-gruppen interferon-alpha2a/vinblastin vs. interferon-alpha2a/interleukin-2/5-fluorouracil. Urologe A 43(9): 1111-1119, 2004

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. Journal of Hepatology 34(1): 128-133, 2001

Effects of amantadine and amantadine/interferon alpha2a on peripheral blood mononuclear cells from chronic hepatitis C patients and healthy donors. Journal of Hepatology 28(Suppl. 1): 104, 1998

The role of triple therapy with amantadine sulphate plus ribavirin and interferon alpha2a on chronic hepatitis c patients. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1258, 2003